Medcura

United States Founded: 2019 • Age: 7 yrs
Developer of the device for controlling bleeding

About Medcura

Medcura is a Healthcare company based in United States founded in 2019. Medcura has raised $87.35 million across 6 funding rounds from investors including TEDCO. Medcura offers products and services including LifeGel and Hemostasis Portfolio. Its focus areas include Life Sciences, Hematology, Medical Devices and Therapeutic. Its competitors include ExThera Medical, CytoPherx and Arteriocyte; 3 of its 3 listed competitors have raised funding.

Company details

Developer of the device for controlling bleeding. The product Triple R is used to rapidly and decisively stop bleeding after diagnostic and interventional vascular access procedures, Life Foam s a self-expanding injectable biopolymer foam to treat internal non-specific hemorrhage, LifeGel for treating bleeding from parenchymal tissue, and Rapid-Seal provides an antibacterial barrier.

  • Headquarters United States
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website medcurainc.com
  • Social LinkedIn X Facebook Instagram
Operational Areas
Key Metrics
  • Total Equity Funding
    $87.35M (USD)

    in 6 rounds

  • Latest Funding Round
    $28.55M (USD), Series C

    Apr 2025

  • Investors

Products & Services of Medcura

Medcura offers a comprehensive portfolio of products and services, including LifeGel and Hemostasis Portfolio.

LifeGel
Hemostatic Gel

Flowable gel for controlling bleeding in surgical procedures

Hemostasis Portfolio
Medical Devices

Biopolymer solutions for minimal to moderate bleeding management

Funding Insights of Medcura

Medcura has successfully raised a total of $87.35M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $28.55 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $87.35M
  • Total Rounds 6
  • Last Round Series C β€” $28.55M
  • First Round $3.02M

    (Sep 2020)

  • Investors Count 1

All 6 funding rounds of Medcura with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2025$28.55MSeries C––
–
Apr 2024$22.4MSeries C––
–
Jul 2022$22.49MSeries C–TEDCO
–
Nov 2021$3.49MSeries B––
–
Aug 2021$7.4MSeries B––
–
Sep 2020$3.02MSeries A––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Medcura

Medcura has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include TEDCO.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Venture capital fund and startup accelerator programs focused on seed and early stage companies
1998tedcomd.comColumbia, United States
Premium access

Investor details for Medcura

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Medcura

16 people are tracked at Medcura (10 in leadership, 3 in board & advisors, 3 in team).

NameRoleGroup
Rachel Hoffman
Senior Vice President, Clinical And Regulatory Affairs / Head Of Translational ResearchLeadership
Jim Buck
President, CEO & DirectorLeadership
Matthew Dowling
Chief Scientific Officer and DirectorLeadership
Rich Vincent
CFOLeadership
Bruce Choi
Head of ManufacturingLeadership
Natasha Johnson
VP, Quality AssuranceLeadership
Jaeho Lee
Associate Director of R&DLeadership
Dave Clark
Head of Strategic PartnershipsLeadership
Steve Ford
Head of Business DevelopmentLeadership
Felix Vega
Director, Pre-Clinical ResearchLeadership
Ed Quilty
DirectorBoard & advisors
Srinivasa Raghavan
Scientific Advisory Board MemberBoard & advisors
Larry Tiffany
Executive Chairman & DirectorBoard & advisors
John Barry
SVP, Product Development & OperationsTeam
Bradon Wallace
Manufacturing EngineerTeam
Brandon Wallace
Manufacturing EngineerTeam
Premium access

Complete people profiles for Medcura

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Medcura

3 dated milestones of Medcura across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded Medcura is founded.
  2. Funding First funding round of $3.0M.
  3. Funding Latest funding round, Series C, of $28.5M.

Competitors of Medcura

Medcura has 3 listed competitors in our database, 3 of them funded. They include ExThera Medical, CytoPherx and Arteriocyte.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
extheramedical.com2007Berkeley, United States$54.59M23
Medical devices for the rapid treatment of bloodstream infections and pathogen-reduction in blood banking
cytopherx.com1994Ann Arbor, United States$45.69M
Cytopheresis systems for inflammatory conditions
arteriocyte.com2007Hopkinton, United States$15.11M7
Devices to facilitate blood component and bone marrow transplant
Premium access

Detailed competitors of Medcura

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Medcura

The website of Medcura (medcurainc.com) receives about 3.1K visits a month.

  • Monthly visits
    3.1K

    ▼ 17.5% vs previous month

Similar websites

Websites whose visitors overlap most with Medcura. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
undifferentiatedmedicalstudent.com
undifferentiatedmedicalstudent.com
100%
#3,453,786–

Top companies in Hematology

3 companies that operate in the same segment as Medcura (Hematology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Catheter-based thrombectomy devices for vascular emboli removal are developed.
2011Irvine, California, United StatesUSD 51.89 MUSD 493.63 M696
Small molecules are developed to treat hematologic and musculoskeletal disorders.
2016Lexington, Kentucky, United StatesUSD 90 MUSD 244.06 M169
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
2016Menlo Park, California, United StatesUSD 300 M384
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Medcura

Premium access

Complete news archive for Medcura

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Medcura

Medcura was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Medcura is headquartered in United States.

Medcura is a funded company, having raised a total of $87.35M across 6 funding rounds to date. The company's 1st funding round was a Series A of $3.02M, raised on Sep 2020.

Developer of the device for controlling bleeding. The product Triple R is used to rapidly and decisively stop bleeding after diagnostic and interventional vascular access procedures, Life Foam s a self-expanding injectable biopolymer foam to treat internal non-specific hemorrhage, LifeGel for treating bleeding from parenchymal tissue, and Rapid-Seal provides an antibacterial barrier.

Medcura's top competitors include ExThera Medical, Arteriocyte and CytoPherx.

Medcura offers LifeGel and Hemostasis Portfolio.

Medcura has 1 investor. Key investors include TEDCO.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available